Raymond James initiated coverage of Pacira with an Outperform rating and $42 price target. Expectations have been lowered “considerably” for the company’s entire non-opioid pain portfolio, says the firm, which sees a much better entry point for the stock at current levels with a favorable risk/reward. The set-up for potential revenue growth from here has improved despite the several macro uncertainties with the portfolio persisting, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira consensus for 2024 looks too high, 2025 too low, says Jefferies
- Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
- Pacira announces FDA approval of expanded EXPAREL label
- Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
- Pacira price target lowered to $50 from $57 at Barclays
